The aim was to analyse the implementation dynamics of the essential medicines list (EML). We used the government expenditures on medicines and Brazil as a case study. Drug purchases were considered as a proxy for utilization. The essential medicines (EMs) expenditures were followed over time by Brazilian National EMLs life-time and defined by broad therapeutic categories and by specific medicines. Brazil increased the number of the medicines during the last four editions of Brazilian National EMLs and the federal government expenditures on them. The EML implementation dynamics changed the distribution of expenditures on EMs. We identified a common set of 404 EMs present in all four editions of the Brazilian National EMLs. There was a proportional decrease in expenditures on anti-infectives for systemic use, blood and blood-forming organs and alimentary tract and metabolism, and increase in expenditures on antineoplastic and immunomodulating agents. The expenditures distribution per specific medicines revealed that a small set of EMs was responsible for 50% or more of expenditures considering Brazilian National EML life-time for all four periods. The increase in expenditures on EMs in Brazil was a consequence of the newer medicines incorporated over time in the Brazilian National EMLs. The use of the medicines expenditures as a source of data and the definition of an EML life-time permitted follow-up of the implementation dynamics of different versions of the Brazilian National EMLs. Our results have implications for policymakers and stakeholders to gain a better understanding of the role EMLs play in health system sustainability and in the provision of the most beneficial heath care.
Medicines play a crucial role in health care and demand a substantial proportion of healthcare expenditures [1] . However, many new medicines introduced to the pharmaceutical market have no added therapeutic value if compared with the existing alternatives, even though their prices are very high [2] . The economic impact of pharmaceuticals has increased over time for governments and for the population, and there are concerns about how governments can continue to provide medicines as insured benefits for the population [3] [4] [5] [6] . Thus, affordable access to 'essential medicines' is one of the eight United Nations Millennium Development Goals [7] .
The World Health Organization (WHO) launched the concept of Essential Medicines (EM) as a way to provide equitable access to medicines and to guide governments towards rational allocation of health resources [8] . EMs are those which attend to priority diseases of a population and must be selected according to the best evidence regarding efficacy and safety, and comparative cost-effectiveness with other therapeutic options [8] . Using the EM concept requires a comparative analysis process that results in a list of medicines called the Essential Medicines List (EML), strategically relevant to countries in different stages of economic development [8] [9] [10] . The concept of EM is internationally recognized as a health strategy to rationalize the use of medicines with beneficial clinical and managerial outcome [2] .
Although the EM concept appears simple, it is complex to implement and maintain. The basis for the EM concept to flourish includes continuous, unrelenting policy focus on health priorities, development of EMLs, rational use of medicines and training of health professionals, physician adherence to EMLs and to clinical protocols, among others. Several factors, such as pressures for adoption of therapeutic novelties, with or without therapeutic gain, faulty professional training, policy agendas not directed to rational use, difficulties in management of health services and of pharmaceutical services and lack of resources may undermine governments' and health system efforts and either stagnate implementation or derail it [4, 5] .
The WHO recommends that each government update their EML every 2 years [11] . At present, 60% of countries have published an EML, but only 10.3% of those countries have updated it in the last 4 years [12] . The objective of the update is to include more cost-effective medicines while removing those that have proven to be less cost-effective or present safety concerns. The EML implementation includes dissemination of the list and adoption by a physician. Listed medicines must then be procured and supplied [8] [9] [10] [11] . Because Author for correspondence: Rachel Magarinos-Torres, 312 -6230 Thunderbird Blvd., Vancouver, BC, Canada V6T0C3 (e-mail racheltorres. uff@gmail.com).
procurement and supply may be perceived as a proxi for utilization, studying expenditures on EMs may be a useful approach to studying the dynamics of EML implementation [13] .
The Brazilian government provides free universal access to medicines for the population through the public health system [14] . The model is prescription-based dispensing through public health pharmacies. The government is responsible for procurement and managing the dispensing of the medicines. The federal state and municipal governments are responsible for procurement and management of medicines supply, while the federal government has the greatest financial burden [14] .
The concept of EM was the focus of the Brazilian National Medicines Policy until 2012. Brazil has had an EML since 1964, and from the year 2000, the list has been routinely updated, functioning as a guide to coverage [15] . However, in 2012, a policy change occurred that resulted in a significant increase in the number of medicines included in the EML and, at the same time, removing anticancer medicines from the EML. Criteria for selection of EMs, one of the basis for the EM concept, were not followed. Medicines were listed based on their financing and procurement status in the public health system. This situation reflects a set of the issues that challenges the adoption of the EM concept and practical application of an EML [16] [17] [18] .
Thus, the objective of this study was to analyse the implementation dynamics of EMLs using medicines expenditures and Brazil as a case study and focusing on four consecutive editions of the Brazilian National EMLs.
Methods
Study design and setting. We conducted a quantitative drug utilization study [13] using Brazilian federal government medicines procurement data from 1 April 2007 to 31 March 2014, corresponding to four consecutive editions of the Brazilian National EMLs. Purchases were considered as a proxy for utilization.
Data sources. The necessary data and information on medicines procurement, medicine description and composition of national EMLs were retrieved from the following sources: (i) the last four editions of the Brazilian National EMLs for depicting listed EMs [19] [20] [21] [22] ; (ii) the General Services Administration System (SIASG) for data on medicines purchases [23] ; (iii) the Brazilian Non-proprietary Names index (DCB) and the International Non-proprietary Names index (INN) which provided medicine nomenclature [24] ; and (iv) the Anatomical Therapeutic Chemical Classification Index (ATC) which provided the ATC codes [25] .
SIASG is a Brazilian public database that provides information on all federal government purchases, including all medicines (http://dad os.gov.br/dataset/compras-publicas-do-governo-federal). All federal government purchases, which include supplies for hospitals, medicines for primary health care as well as medicines for medium and highly complex care, must be registered in SIASG [23] . Variables in SIASG include name of active substance, dosage form and strength, date of purchase, quantity purchased, actual procurement price, manufacturer/ supplier/vendor. All variables pertaining to a specific purchase correspond to only one medicine.
Data analysis.
Identification of temporal setting, essential medicines and variable definitions. During the study period, Brazil produced four EMLs. The EML life-time was defined as the interval ranging from the 6th month after the publication of one list to the 6th month after publication of the following list. This definition considered two variables: the average procurement time in the public health system (which is also regulated by law) [26, 27] and the necessary time to disseminate the newly produced list in the public health system [28, 29] . Each EML presented a different set of EMs and a specific EML life-time. Variables included active substances, dosage form, strength, date of purchase, quantity and unit price.
Five different subsets of EMs were identified. The first four sets were of EMs contained in the 2006, 2008, 2010 and 2012 editions of the Brazilian National EMLs. The fifth set was defined as being composed only by the medicines which were common to all four Brazilian National EMLs. The purpose of this analysis was to identify medicines that were perceived as a priority during the period. Indexing of medicines was performed with the help of DCB, INN and the ATC code.
Medicines expenditures. For each Brazilian National EML life-time, (i) we calculated the total expenditures for all medicines purchases by the Brazilian Federal Government; (ii) total expenditures on EMs listed in each EML edition (four subsets); and (iii) total expenditures of EMs common to all editions of the Brazilian National EML (fifth subset).
We also calculated (iv) the percentage of EMs expenditures relative to total medicines expenditures, per month, during each Brazilian National EML life-time; (v) the EMs expenditures by broad therapeutic category (ATC level 1) considering the Brazilian National EML life-time; and (vi) the most expensive medicines (ATC level 5) per Brazilian National EML life-time. These were described as the ones that together constituted 50% of all expenditures per EML.
Medicines expenditures were determined by multiplying the actual procurement unit price of each medicine by total quantity purchased. Quantity was established as number of packages times number of units per package. All expenditures were adjusted to March 2014 reais (R $), according to the Brazilian Consumer Pricing Index, and further adjusted to USD, according to National Bank of Brazil exchange values (1 dollar = 2,2354 reais). We traced a logarithmic trend curve considering the best fit (r2) for follow-up of the monthly expenditures of EMs by EML life-times. All analyses were carried out in SPPS (IBM, version 14.0) and Tableau (Tableau Foundation, 9.2 Student, 2015, Seattle, Washington, EUA.). The top medicines in terms of expenditures match with the top four ATC groups ( fig. 3) . It is important to note, however, that a small number of medicines were responsible for more than 50% of EMs expenditures per Brazilian National EML life-time and this holds true in all EML edition life-times. These medicines, however, varied for each Brazilian National EML edition ( fig. 3 ). Coagulation factor VIII is the only medicine that appears in top positions for all four EML edition life-times. Pneumococcus vaccine, etanercept, adalimumab and tacrolimus were included in the Brazilian National EML in 2012. The sum of their joint expenditures was 193.6% greater than the sum of expenditures of the two top medicines in the EML 2012 (Insulin and coagulation factor VIII).
Results
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The current study shows that the number of medicines and related expenditures in the Brazilian National EMLs increased during the study period. The expansion differed over time in respect to which medicines were added, and the distribution of expenditures also changed as a consequence. There was a proportional decrease in expenditures on medicines within the categories anti-infectives for systemic use (Group J), blood and blood-forming organs (Group B) and alimentary tract and metabolism (Group A). On the other hand, the expenditures on antineoplastic and immunomodulating agents (Group L) sharply increased during the Brazilian National EML 2012 life-time and bloated the total of expenditures on EMs.
A common set of EMs appeared in all Brazilian National EML editions. Percentage of expenditures with this common set of medicines fell over time during the entire study period in comparison with total medicines expenditures and also to expenditures with EMs. Priorities for the health system tend to change over time, but not very suddenly. As such, percentages of a common group of medicines present in all EMLs should not vary suddenly. Furthermore, it was only in 2013 that the WHO included 'public health relevance' as an alternate criterion for an inclusion of EMs in EMLs (30), favouring medicines for less incident or prevalent diseases. This might justify new inclusions in the 2012 Brazilian National EML edition, accepting that this trend reached the country before WHO made it official policy. However, as also described by this study, the expenditures on the common set of EMs fell abruptly in the 2012 National Brazilian EMLs life-time (Groups A, B and J) while ATC Group L increased, also abruptly, in that same EML edition, showing specific turnover targets in the list. As such, the examination of a common set of medicines that are present in successive EML editions, together with an in-depth description of medicines in, and out of, this set is a reasonable screening method for assessing EML implementation dynamics, turnover and possibly velocity of medicines incorporation.
The increase in expenditures on EMs in Brazil was a consequence of the newer medicines incorporated over time in the Brazilian National EMLs. Our data show an important increase in expenditures on EMs listed in the 2012 Brazilian National EM. This increase was associated with both technical and legislative change. Until 2011, medicines in the Brazilian National EMLs were selected through an evidence-based therapeutic and financial perspective. Financial pressures resulting from health litigation [31, 32] compelled the government to rapidly incorporate costly medicines and to produce an all-inclusive procurement list naming it an 'EMs' list. All publicly financed medicines were included, resulting in a significant expansion of the 2012 Brazilian National EML edition and, as such, distancing the selection process from the EM concept and its role in reflecting therapeutic need. Demand substituted need as the driving force for list management. The greatest decrease trend in EMs expenditures occurred during 2012 Brazilian National EML life-time, possibly showing fluctuating demand during this period, exactly because listed medicines may not be, in fact, EMs, and not exactly meeting EM criteria such as health priorities, disease prevalence and the best evidence regarding efficacy, safety and effectiveness [15, 33] .
The rapid inclusion of very expensive medicines on the 2012 Brazilian EML perhaps with the hope that prices would be reduced goes against the principles of EMs selection and seemingly has little effect on the price reduction [17] considering the cost of adverse drug events [34] . Furthermore, we rarely noticed a reduction in expenditures due to price reduction over time. Although some high-cost medicines may have suffered patent expiry during the period of analysis, the shear might of new patented drug inclusions overshadowed any decreasing trend from loss of patents [2] .
In recent years, an enormous number of lawsuits have forced the Brazilian government to purchase several innovative immunomodulating agents. The incorporation of these medicines in the 2012 Brazilian National EML was a response to this pressure [35] . Considering the global burden of disease in Brazil, there is no epidemiological justification for inclusion of these medicines in the national EML [15] . What we may observe is the direction of more financial resources to the needs of a small proportion of the population for which there is an opportunity cost. The cost of the immunomodulators is also affecting high-income countries, which have to allocate a large budget for high-priced drugs [36, 37] . Brazil has so far not progressed in managed entry of these innovative highpriced drugs, as have European countries [38, 39] The allocation of financial resources guided by the prevalence of diseases, core to the concept of EM, invites discussion about individual rights versus collective rights to access to medicines [40, 41] . On one hand, the establishment of the EML shows health priorities and drives the allocation of resources to where they are most needed, but on the other hand, it may restrict the population's access to specific medicines [42] . The pressure to incorporate high-cost drugs for rare diseases in an EML is a reality in various countries [43, 44] . This pressure also seems to affect the WHO Model List. The moving forward challenge is to define a complementary list of medicines using as the magnitude of the clinical benefit and the favourable riskbenefit profile as the primary criteria [17, 30] .
Even though procurement of medicines may not be constant concerning what is purchased or when, in particular in countries that provide universal access to medicines [28] , the analysis of the trend of expenditures during each EML life-time helps to view the effectiveness of the EML. An EML includes a set of core medicines -EMs that are maintained in the list, over time -that enables large-scale purchases by the government, which, in turn, decreases expenditures [11, 28] . The 2008 Brazilian National EML was the one in which expenditures fluctuated the least, showing perhaps a constant adherence to EMs purchases. On the contrary, the 2012 list showed the greatest decrease trend in EMs expenditures during its lifetime, possibly as a result of the large-scale purchases of costly new medicines incorporated in the 2012 Brazilian National EML.
Furthermore, even if Brazil has undergone epidemiological transition and chronic diseases are now the most prevalent in the country [45] , it is worth highlighting that the 2012 Brazilian National EML removed all anticancer medicines (L01). In our analysis, from the perspective of ATC level 1, anticancer medicines were present in the 2006, 2008 and 2010 National Brazilian EML editions, but not in the 2012 edition [19] . These medicines are now included in complex-care protocols and are not listed as EMs, thus not participating in EM expenditures [46] . As such, we must view the observed increase as a rise not encumbered by costly cancer treatments. Expenditures for the L group should be, therefore, related to other indications for immunomodulators [47, 48] .
Limitations of this research include the lack of the information about EMs expenditures from states and municipalities. Although in Brazil, the federal government has the greatest financial participation, state and municipal governments also have tiered responsibility in providing EMs [14] . This limitation precludes comment on the regional utilization of EMs and also of medicine use at individual patient level. The SIASG database is an aggregated national database of medicine purchases and does not allow an assessment of dispensed/prescribed medicines at the individual patient level [23] .
Our analyses were based strictly on federal government data. Our values are a proxi for all public expenditures on EMs, which are undertaken also by state and municipal governments. However, our goal was not to describe EMs expenditures as mere value or their shares but to understand EMLs dynamics through the spyglass of federal expenditures, as an approximation, and for this goal, the data set we used was adequate. Furthermore, the Brazilian National EMLs is drafted by the Federal Government and is bound by policy to uphold procurement by that standard, which is not the case with state and municipal governments [14, [19] [20] [21] [22] .
Despite these limitations, our results have implications for policymakers and stakeholders, to gain a better understanding of the role EMLs play in health system sustainability and in provision of the most beneficial heath care. The study was based on national data, and we believe that the methodological design contributed to a more comprehensive analysis of the medicine utilization framework than those proposed by previous studies, which explored the availability of EMs in a public or private perspective [4, [49] [50] [51] .
The analysis of the implementation dynamics of EMLs opens the discussion regarding the allocation of financial resources for medicines provision for prevalent diseases in a global perspective, in terms of the ways to provide treatment for less common diseases, on how to sustain medicines for prevalent diseases while adding newer, costly but very effective medicines to the list. This analysis may also provide insight on how expenditures behave over time and if the inclusion of new drugs harms the maintenance of other medicines in the list. The EM concept traditionally shuns the inclusion of new drugs, because of unproven safety due to an insufficient 'exposure' record. So, decisions to include new drugs, which will induce the reallocation of substantial resources, must be firmly backed by consistent evidence while considering possible trade-offs, such as the decrease of the core EMs.
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